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Abstract
In viral pandemics, most specifically Covid-19, many patients with neuroendocrine neoplasms (NENs), including 
phaeochromocytomas, paragangliomas and medullary thyroid carcinoma, may develop Covid-19 in a mild or 
severe form, or be concerned about the influence of viral infection relative to their anti-tumoral therapy. In general, 
newly presenting patients should be assessed, and patients recently receiving chemotherapy, targeted therapy or 
radionuclide therapy, or showing tumour growth, should be closely followed. For previously diagnosed patients, 
who have indolent disease, some delay in routine follow-up or treatment may not be problematic. However, patients 
developing acute secretory syndromes due to functional neuroendocrine neoplasms (such as of the pancreas, 
intestine or lung), phaeochromocytomas and paragangliomas, will require prompt treatment. Patients with life-
threatening Covid-19-related symptoms should be urgently treated and long-term anti-tumoral treatments may be 
temporarily delayed. In patients with especially aggressive NENs, a careful judgement should be made regarding the 
severity of any Covid-19 illness, tumour grade, and the immunosuppressant effects of any planned chemotherapy, 
immunotherapy (e.g. interferon-alpha), targeted therapy or related treatment. In other cases, especially patients with 
completely resected NENs, or who are under surveillance for a genetic disorder, a telephone or delayed consultation 
may be in order, balancing the risk of a delay against that of the possible development of Covid-19.
Introduction
 • SARS CoV2 viruses (Covid-19) bind to angiotensin-
converting enzyme-2 (ACE2), a cell-surface receptor, 
and a potential interaction between Covid-19 and 
the renin-angiotensin-aldosterone system has been 
reported (1, 2, 3, 4). However, such interactions 
between Covid-19 or other SARS viruses and receptors 
expressed on neuroendocrine neoplasms (NENs), 
such as somatostatin receptors (SSRs) and histamine 
receptors (H1 and H2 receptors), have not been 
reported.
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 • The specific effects of Covid-19 infection in patients 
with NENs have not as yet, to our knowledge, 
been reported.
 • Neuroendocrine neoplasms (NENs) are rare neoplasms 
arising from cells of the diffuse endocrine system, 
mainly dispersed throughout the digestive system 
and respiratory tract. Most NENs grow slowly and 
symptoms may be related to tumour mass (non-
functioning, NF-NENs) and/or to the hypersecretion of 
hormones (functioning, F-NENs). Histopathologically, 
most NENs are well-differentiated (WD) tumours grade 
1 (G1, Ki67 ≤2%), grade 2 (G2, Ki67 3–20%) or grade 3 
(G3, Ki67 >20%), whereas a small fraction are defined 
as poorly differentiated (PD) neuroendocrine small-
cell or large-cell carcinoma (NEC) with a Ki67 >20% 
(5, 6).
 • Patients with NENs and severe infections causing 
respiratory difficulties or gastrointestinal (GI) 
symptoms (e.g. diarrhoea, nausea and vomiting) are 
likely to present to hospital. Such ill patients may 
not be able to take their prescribed medication (e.g. 
analgesia, anti-diarrhoeals, proton pump inhibitors, 
oral chemotherapy drugs, targeted drugs), or the 
medication may not be absorbed, and these patients 
may require admission for treatment.
 • Some patients presenting with Covid-19 infection 
may have an underlying undiagnosed NEN, and this 
possibility should be considered in those patients 
whose symptoms, for example, diarrhoea, or wheeze 
with shortness of breath, are not resolving, or whose 
symptoms were chronic.
Management of patients with NENs and 
Covid-19 infection
 • There are currently no drug-treatments or vaccines 
available for Covid-19, and therefore, managing 
patients with NENs alongside Covid-19 is likely to be 
an ongoing challenge for many months.
General measures
 • The general measures for treatment are the same as in 
any other patient with Covid-19 infection and should 
involve acute management of airway, breathing and 
circulation.
Specific measures
 • Specific emergency treatments may need to be directed 
to the NEN (Table 1).
 • Surgery (or endoscopic removal) is the only curative 
option for localised NENs (7). For those patients with 
compressive symptoms or acute complications, surgery 
may need to be considered during the Covid-19 
pandemic (Fig. 1). For patients with localised disease 
who are asymptomatic, surgery could be reasonably 
delayed for 8–12 weeks.
 • Patients with NENs who have had prior treatments 
(e.g. surgery, chemotherapy, everolimus, sunitinib, or 
radionuclide therapy) may have developed sequelae 
such as diabetes mellitus, or be on glucocorticoids, 
or be immuno-compromised, which will make them 
vulnerable to the severe complications of Covid-19 
infection.
 • NENs may arise in any organ, and those occurring 
in the respiratory tract (referred to as carcinoids), 
gastrointestinal (GI) tract and pancreas (referred to as 
GEP-NENs), thyroid, and adrenal (Table 1).
 • NENs may occur with other tumours in patients 
with heritable endocrine tumour syndromes, such as 
multiple endocrine neoplasia (MEN) and von Hippel-
Lindau disease (VHL). There are four major forms 
of MEN. In MEN1, pancreatic and lung (and rarely 
thymic) NENs occur with parathyroid tumours and 
anterior pituitary adenomas (8). In MEN2 (previously 
MEN2A), medullary thyroid carcinoma (MTC) occurs 
with phaeochromocytoma and parathyroid tumours, 
while in MEN3 (previously MEN2B) parathyroid 
tumours are rare, and the occurrence of MTC and 
phaeochromocytoma is found in association with a 
marfanoid habitus, mucosal neuromas, medullated 
corneal fibers, and intestinal autonomic ganglion 
dysfunction leading to megacolon (9). In the very rare 
MEN4, parathyroid adenomas, pituitary adenomas, 
and pancreatic NENs occur in association with 
gonadal, adrenal, renal and thyroid tumours. In 
VHL pancreatic NENs and PPGL occur in addition to 
haemangioblastomas and renal cell carcinoma.
 • Based on our experience/knowledge gained from the 
consequences of other severe infections in patients 
with NENs, and on expert opinion, a brief overview 
of NENs for the non-specialist is given together with 
specific management recommendations for individual 
conditions (Figs 1 and 2) and service provision during 
the Covid -19 pandemic.
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(i) Neuroendocrine neoplasms of the 
respiratory tract and thymus
Bronchial carcinoids
 • Bronchial carcinoid tumours can secrete serotonin, 
vasoactive substances and other hormones directly 
into the systemic circulation (Table 1) (8).
 • Bronchial carcinoids may present with bronchial 
obstruction, cough, haemoptysis, weakness, nausea, 
weight loss, and neuralgia, or incidentally on chest 
imaging.
 • Diffuse idiopathic pulmonary neuroendocrine cell 
hyperplasia (DIPNECH) can also cause acute respiratory 
symptoms and may be difficult to differentiate from 
Covid-19 infection on chest x-ray or conventional 
cross-sectional imaging. We advise prioritising Covid-
19 testing for such patients. If viral testing is negative, 
a biopsy to provide a definitive diagnosis should be 
considered.
Figure 1
A suggested approach to surgical decision making during the Covid-19 pandemic for patients with NENs. *The patient’s prognosis 
and life-expectancy from the underlying NEN must be considered in each case and discussed with the patient, family and surgical 
team. **Locally ablative therapies e.g. RFA, radio-embolisation or PRRT could be considered as an alternative to surgery in select 
patient’s. ***This is not an exhaustive list but designed as a guide and all non-emergency surgical cases should be discussed at a 
specialist NEN MDT. ****Age over 60, pre-existing cardiovascular disease, pre-existing respiratory disease. CHD, carcinoid heart 
disease; PPGL, phaeochromocytoma/paraganglioma; pNEN, pancreatic neuroendocrine neoplasm; SI NEN, small intestine 
neuroendocrine neoplasm; PRRT, peptide receptor radionuclide therapy; SSA, somatostatin analogues; RFA, radiofrequency 
ablation; GEP, gastro-enteropancreatic





















 • Thymic NENs may cause compression of the trachea 
and mediastinal blood vessels and may secrete 
hormones.
(ii) Gastrointestinal neuroendocrine 
neoplasms (GI NENs)
 • GI NENs may be asymptomatic or they may present 
with obstructive symptoms (pain, nausea, vomiting), 
or with symptoms due to hormonal secretion.
 • For major NEN surgery prophylactic perioperative 
treatment with i.v. octreotide, a somatostatin 
analogue (SSA), at a starting dose of 50–100 µg/h, is 
used to prevent carcinoid crisis (9) (see below), and 
drugs that stimulate the sympathetic nervous system 
or cause histamine release such as morphine and 
D-tubocurarine are avoided. Well-differentiated grade 
3 GI NENs with a Ki-67 <55% should be treated as for 
grade 1 and 2 GI NENs unless there is evidence of rapid 
tumour growth, in which case they should be treated 
as for poorly differentiated NECs (10).
 • Irrespective of Covid-19 risk, NECs should be treated 
urgently with appropriate chemotherapy (10, 11).
 • NEC patients being treated with chemotherapy may 
be immunocompromised and therefore at high risk for 
Covid-19.
Figure 2
A suggested approach to the timing of clinical assessment during Covid-19 for new and follow-up patients with NENs. *The 
timelines and type of surveillance should follow local and ENETS guidelines where possible. **The diagnosis may be based on 
limited biochemical and radiological data and clinical judgement should be applied. PPGL, phaeochromocytoma/paraganglioma; 
pNEN, pancreatic neuroendocrine tumour; PRRT, peptide receptor radionuclide therapy; SSA, somatostatin analogues; NEC, 
neuroendocrine carcinoma; MTC, medullary thyroid carcinoma.

















183:3 G84Clinical Practice Guidance R T Casey and others NENs management during 
Covid-19
https://eje.bioscientifica.com
 • If a NEC is discovered in a patient with severe Covid-19, 
the respiratory illness should be treated first, followed 
by early and appropriate chemotherapy following 
recovery.
Small intestinal (SI) NENs
 • SI NENs, which can produce serotonin and other 
vasoactive substances, may present with loco-regional 
disease or distant metastatic disease and are associated 
with estimated five-year survival rates of 65 and 35%, 
respectively (8).
 • Loco-regional disease may present with abdominal pain 
due to mesenteric venous insufficiency, auto-infarction 
with tumour necrosis and haemorrhage, serotonin-
induced retroperitoneal fibrosis, hydronephrosis or 
small bowel obstruction, which may require surgical 
intervention as an emergency.
 • Metastatic and systemic disease may result in 
features of the carcinoid syndrome, which occurs in 
approximately 20% of SI NENs. Features of carcinoid 
syndrome include facial flushing, angioedema, 
diarrhoea, wheeze, ascites, pellagra and symptoms of 
right-sided heart failure caused by fibrosis of right-
sided heart valves, so-called carcinoid heart disease 
(CHD). Some patients have lacrimation, rhinorrhoea, 
and episodic palpitations when they flush.
 • The first-line therapy for patients with metastatic 
carcinoid is a long-acting SSA (e.g. octreotide LAR 
or lanreotide autogel) which has anti-proliferative 
and anti-secretory benefits in NENs (12, 13). Anti-
diarrhoeal drugs (e.g. loperamide, codeine phosphate) 
and anti-histamines (blocking histamine 1 (H1) and 2 
receptors (H2) for flushing may help some patients.
 • At present there is no evidence to suggest that SSAs 
increase the risk of Covid-19 infection.
 • SSAs can cause QT prolongation, and choice of anti-
microbial and/or cardiac monitoring should be 
carefully considered for patients with Covid-19 taking 
SSAs (14) (Table 1).
 • Treatment with telotristat ethyl may be considered 
in some centres for the management of refractory 
diarrohea in patients with carcinoid syndrome.
 • A carcinoid crisis is a medical emergency caused by 
the sudden release of serotonin and other vasoactive 
substances into the systemic circulation and is 
characterised by intense flushing, bronchospasm, 
tachycardia, labile blood pressure (hypertension or 
profound hypotension) (15). A carcinoid crisis may 
look like an anaphylactic attack, but adrenaline must 
not be given as it will provoke, not help, carcinoid 
attacks (see below and Table 1) (15, 16).
 • Common precipitants of a carcinoid crisis include: 
(i) intra-operative handling of the primary tumour; 
(ii) biopsy or ablative therapies of a tumour; (iii) 
anaesthetic induction; and (iv) specific medications 
such as cyclizine, long-acting vasopressors (e.g. 
noradrenaline) and drugs which stimulate histamine 
release (e.g D-tubocurarine) (Table 1).
 • Treatment for a carcinoid crisis comprises an i.v. bolus 
of octreotide (25–500 µg) followed by an i.v. infusion 
of octreotide at a starting dose of 50–150 µg/h, 
together with i.v. fluids and appropriate cardiovascular 
measures to treat the likely intracardiac hypovolaemia 
and decreased pulmonary artery pressure (8, 7, 16).
 • At present, there are no data regarding the risk of a 
carcinoid crisis in patients with carcinoid syndrome 
who develop acute viral infections, but patients 
with carcinoid heart disease may suffer significant 
decompensated heart failure.
Large intestinal (LI) NENs
 • LI NENs may present with obstructive symptoms 
(pain, nausea, constipation and diarrhoea), weight 
loss, or rectal bleeding, loco-regional disease similar to 
SI NENs, and rarely carcinoid syndrome (see above) (8).
(iii) Pancreatic NENs
 • PNENs may secrete endogenous hormones or be non-
hormone secreting (non-functioning) (Table 1).
 • Surgery is the treatment of choice for non-metastatic 
PNENs measuring 2 cm or greater in size, as it is often 
curative (7, 9).
Insulinomas
 • Hypoglycaemia in association with neuroglycopenia 
symptoms that are relieved by administration of 
glucose are the cardinal features (Whipple’s triad) 
(Table 1) (9, 17).
 • The combination of hypoglycaemic symptoms with 
documented hypoglycaemia (blood glucose <2.2 
mmol/L) with hyperinsulinaemia (>30 pmol/L) and 
inappropriately increased circulating C-peptide (>300 
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pmol/L), in the absence of sulphonylurea or related 
drugs, in the plasma and urine is pathognomonic of 
insulinoma.
 • Hydroxychloroquine as a treatment for Covid-19 can 
cause hypoglycaemia, which should be differentiated 
from hyperinsulinaemic hypoglycemia.
 • Hypoglycaemia is an emergency. Initially in a 
conscious and cooperative patient, glucose 10–20 g 
(e.g. 2–4 teaspoons (or 3–6 lumps) of sugar, 150–200 
mL of pure fruit juice, or 5–7 tablets of dextrose) 
can be given orally. In an unconscious patient i.v. 
administration of glucose is required (e.g. 50 mL of 
20% glucose (dextrose) infusion over 10 min, into 
a large vein through a large-gauge needle since this 
concentration is irritant especially if extravasation 
occurs). Glucagon 1 mg i.m. may be used as an 
alternative.
 • Frequent meals (or enteral feeding via nasogastric tube) 
with diazoxide can be started before proceeding more 
definitive treatment, for example, surgery.
 • Somatostatin analogues (SSAs) can be effective, but 
need careful monitoring as they can worsen the 
hypoglycemia. Corticosteroids may benefit some 
patients.
Gastrinomas
 • Gastrinomas, which are most often located in the 
duodenum, but also occur in the pancreas, are 
associated with marked gastric acid production and 
severe peptic ulcers that are multiple and recurrent 
(Zollinger-Ellison syndrome). Some patients may also 
have diarrhoea (steatorrhoea) (9).
 • Patients with severe haematemesis may need blood 
transfusions and i.v. fluid resuscitation, but for 
patients with Covid-19 and clinical or radiological 
evidence of pulmonary congestion, caution with i.v. 
fluid resuscitation is warranted.
 • Medical treatment, which is directed to reducing 
gastric acid production, comprises high-dose proton 
pump inhibitors, which in severe cases may need to be 
combined with H2 blockers.
Other PNENs
 • The diagnosis and treatments of other PNENs is 
detailed in Table 1.
(iv) Phaeochromocytoma 
and paragangliomas
 • Phaeochromocytomas and paragangliomas (PPGL) may 
present with paroxysmal or sustained hypertension, 
and attacks of palpitations, tremor, perspiration, 
headache and anxiety (18).
 • Patients with previously-treated PPGL should perform 
interval home monitoring of blood pressure and can 
be advised that their risk of Covid-19 is not increased. 
Regular review in asymptomatic patients can be 
delayed (Fig. 2).
 • If admitted with Covid-19, no special requirements 
should be necessary, but plasma and urinary 
metanephrines may be grossly elevated during severe 
disease so should not necessarily be indicative of 
recurrent tumour.
 • If a patient with Covid-19 is suspected of harbouring 
a PPGL and this has been biochemically proven, 
α-adrenoreceptor blockade should be instituted 
(oral with phenoxybenzamine or doxazosin, or 
i.v. phenoxybenzamine) with monitoring of blood 
pressure, and may be considered for β-adrenoreceptor 
blockade after adequate α-adrenoreceptor blockade 
(18).
 • With adequate and appropriate sympathetic blockade, 
PPGL surgery could be postponed during an acute 
Covid-19 crisis (Fig. 1).
(v) Medullary thyroid carcinoma (MTC)
 • MTC may present as a palpable mass in the neck, which 
may be asymptomatic or associated with symptoms of 
pressure, dysphagia, diarrhoea or flushing.
 • Diagnosis of MTC is based on histopathology (high 
calcitonin and or CEA may help but are not diagnostic)
 • MEN2 patients with MTC may also have 
phaeochromocytoma, which must be excluded before 
undertaking any surgical intervention (19).
 • Ectopic ACTH production by MTC may cause Cushing’s 
syndrome.
 • Metastatic MTC can be treated with limited surgical 
resection, external beam radiotherapy in certain 
situations, tyrosine kinase inhibitors (TKIs), SSAs or 
other agents.
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(vi) Specific recommendations for the 
management of NENs during Covid-19
i. Multi-disciplinary meetings (MDT)
 • Specialist NEN MDT meetings will be crucial during 
this period to ensure on-going governance and 
appropriate decision making. For each case, the risk 
of the proposed intervention, diagnostic procedure 
or treatment should be weighed up against the risk of 
hospital attendance and Covid-19.
 • MDT meetings should have options for videoconference 
and virtual meetings.
ii. Surgery for NENs
See Figure 1.
iii. Clinical review for NEN patients
 • Non face-to-face consultations including phone 
or video consultations for suitable patients is 
recommended (Fig. 2).
 • Non-essential clinic consultations should be postponed 
(Fig. 2).
Clinical review should be carried out with necessary 
safety precautions in place (Fig. 2).
iv. Radiological surveillance for NEN patients
 • Cross-sectional imaging should be considered for 
patients with suspected disease progression, based 
on clinical symptoms, biochemistry or anticipated 
tumour biology.
 • Routine surveillance in asymptomatic patients, in 
whom suspicion of disease progression is low, could 
be delayed.
 • Access to nuclear imaging may be limited by Covid-19 
pandemic, and patients considered for peptide receptor 
radionuclide therapy (PRRT) with 177Lutetium-dotatate 
should be prioritised for somatostatin receptor 
imaging (SRI).
v. Endoscopic procedures for NENs
 • Endoscopy department closure or restriction may 
affect diagnosis of and interventions for NENs. SRI may 
be considered as an alternative to endoscopy-guided 
biopsy in certain cases. Individual centres should 
discuss alternative planning for emergency endoscopic 
procedures for patients with NENs during Covid-19.
vi. Therapy for NENs
 • Management of acute presentations due to secretory 
NENs is reviewed in Table 1.
 • Patients with Covid-19 have an increased risk of 
venous thromboembolism (VTE) (20). We recommend 
that patients with NEN and Covid-19 receive VTE 
prophylaxis in accordance with local protocols unless 
there is a significant contraindication, in which case 
careful discussion with a haematology specialist 
is advised.
 • Conservative fluid resuscitation is generally 
recommended for patients with Covid-19 (21), but 
we advise that the i.v. fluid requirements for patients 
with Covid-19 and secretory NENs (e.g patients 
with VIPoma and PPGL) is guided by careful clinical 
assessment, blood pressure, electrolytes and invasive 
monitoring when necessary.
 • For patients on active therapy who develop Covid-19, 
we recommend that treatment is withheld during the 
illness with the exception of SSAs for symptomatic 
secretory NENs.
 • Options for home administration of SSA should be 
explored with patients and family.
 • SSA therapy should be commenced in the absence of 
confirmatory SRI when delayed during the Covid-19 
pandemic.
 • SSA therapy can be considered as a bridge to a 
postponed curative surgery in asymptomatic patients 
with localised well-differentiated and non-secretory 
NENs.
 • High-dose SSA therapy may be considered as a 
potentially safer alternative to PRRT, targeted therapy, 
or chemotherapy in patients with progressive well-
differentiated GEP NENs (22).
 • PRRT with 177Lutetium- dotatate therapy 
and other radionuclide therapies (e.g. 
131I-Metaiodobenzylguanidine (131I-MIBG)) should 
be discussed at specialist NEN MDTs. Radionuclide 
therapies should be strictly performed according to 
international protocols, and if cytopaenia develops 
treatment cycles may need to be delayed or postponed.
 • Monitoring for patients receiving PRRT and other 
radionuclide therapies should continue according to 
local guidelines.
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 • Patients may develop treatment-related fevers, 
leucopenia and lymphopenia post-PRRT and 131I-MIBG 
therapy. The differential diagnosis of Covid-19 should 
be considered and testing prioritised to exclude this 
diagnosis.
 • Cytotoxic chemotherapy should be discussed at 
specialist NEN MDTs and alternative lower risks 
options considered for each patient.
 • Local ablative therapies should be considered as an 
alternative to surgery or systemic chemotherapies in 
suitable patients.
 • External beam radiotherapy should only be considered 
in patients with symptomatic bone metastases not 
responding to conventional analgesia.
vii. Discussing resuscitation status for 
NEN patients
 • Discussions regarding resuscitation and escalation 
of care for patients with NENs and Covid-19 should, 
when possible, involve NEN specialists for advice on 
treatments, prognosis and end-of-life measures related 
to the underlying NEN.
viii. Support and educational resources
 • Advice and support for NEN patients and 
families is provided at: www.amend.org.uk, www.
netpatientfoundation.org, and paradifference.org.
ix. Collecting data on patients with NENs 
and Covid-19
 • We recommend recruiting patients with a diagnosis of 
NEN and COVID-19 to a dedicated registry (e.g. https://
endo-ern.eu/ese-and-endo-ern-launch-an-initiative-
to-collect-data-on-patients-with-rare-endocrine-
conditions-and-covid-19/) in order to better inform 
future management of this patient group during the 
Covid-19 pandemic.
Disclaimer
Due to the emerging nature of the Covid-19 crisis this 
document is not based on extensive systematic review 
or meta-analysis, but on rapid expert consensus. This 
document should be considered as guidance only; it 
is not intended to determine an absolute standard of 
medical care. Healthcare staff needs to consider individual 
circumstances when devising the management plan for a 
specific patient.
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